Cyclacel Pharmaceuticals, Inc. (CYCCP)

Market Cap	46.88M
Revenue (ttm)	43,000
Net Income (ttm)	-11.21M
Shares Out	207.34M
EPS (ttm)	-2.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	3.290 - 17.000
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	May 9, 2025

About CYCCP

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: CYCCP
• Website: https://www.cyclacel.com

Financial Performance

In 2024, Cyclacel Pharmaceuticals's revenue was $43,000, a decrease of -89.76% compared to the previous year's $420,000. Losses were -$11.21 million, -50.73% less than in 2023.